{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"96","value":"21.1"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"70","value":"19.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Time from start of treatment until death from any cause.","dispersionType":"Full Range","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Sunitinib -- Cohort A"},{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Sunitinib -- Cohort B"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to two years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"weeks"}